OOrikine Bio
Orikine Bio is a Barcelona-based biotech spin-off from the Centre for Genomic Regulation (CRG) that designs precision-engineered, bi-specific cytokines (its proprietary Foldikine platform) to treat autoimmune and inflammatory immune-mediated diseases. Founded in 2022, it closed a €5.5M seed round led by Sabadell Asabys and AdBio Partners, and has added public non-dilutive funding including CDTI/INNVIERTE, NEOTEC (€335k) and a €800k CPP23 award. It is headquartered in the Barcelona Science Park.
SectorsBiotech, Therapeutics, Immunology, Protein Engineering, Healthtech & Bio
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
A
Ariadna Montero Blay
Scientific Founder & Head of Biology
J
Javier Delgado
Scientific Founder & Advisor
L
Luis Serrano
Scientific Founder & Advisor
Global models 4
AAsher Biotherapeutics
United States · www.asherbio.com ↗
VC-backed biotech engineering cytokines that act only on chosen immune cells, now also moving into immune-mediated disease, with the goal of licensing or partnering its drugs.
~$220MComparable
BBright Peak Therapeutics
Switzerland · www.brightpeaktx.com ↗
Makes precision-engineered and immunocytokine drugs, including IL-2 designs aimed at autoimmune disease, built on its own engineering platform.
~$200MComparable
SSynthekine
United States · www.synthekine.com ↗
Platform biotech that designs engineered cytokines to switch on specific immune signals, including programmes for autoimmune and inflammatory disease.
~$190MComparable
P
Pandion Therapeutics
United States
Built bispecific cytokine drugs such as IL-2 muteins aimed at specific tissues for autoimmune disease, and was bought by Merck for $1.85B.
~$135MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 3
Open as list →
Funding rounds 2
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-02-02 | Seed (estimated) | €2.7M |
Lead not disclosed
+3 more
|
| 2023-07-18 | Seed | €5.5M | Sabadell Asabys, AdBio Partners |
News 6
Open as list →| Published | Article |
|---|---|
| 2026-05-13 |
Christian Pangratz, CEO of Orikine Bio: "We're advancing from research into preclinical development to address a specific type of inflammation that underlies severe inflammatory diseases" ↗
Parc Científic de Barcelona
2026-05-13 |
| 2026-02-02 |
Orikine Bio receives €2.7M in investment from CDTI Innovación together with two other investors ↗
Parc Científic de Barcelona
2026-02-02 |
| 2026-01-20 |
Orikine Bio appoints Larry Edwards as Chairman of the Board ↗
Parc Científic de Barcelona
2026-01-20 |
| 2026-01-14 |
Orikine Bio settles in the Science Park to advance the design of innovative immunotherapies ↗
Parc Científic de Barcelona
2026-01-14 |
| 2024-12-04 |
Orikine Bio secures €800k in innovation research funding to advance groundbreaking autoimmune disease therapy ↗
BioSpace
2024-12-04 |
| 2024-11-04 |
Barcelona's fresh wave of innovation: 10 early-stage startups to keep an eye on ↗
EU-Startups
2024-11-04 |